VNDA vs. GOSS, AKUS, ALBO, ANAB, DVAX, INVA, IRWD, OPK, EBS, and LXRX
Should you be buying Vanda Pharmaceuticals stock or one of its competitors? The main competitors of Vanda Pharmaceuticals include Gossamer Bio (GOSS), Akouos (AKUS), Albireo Pharma (ALBO), AnaptysBio (ANAB), Dynavax Technologies (DVAX), Innoviva (INVA), Ironwood Pharmaceuticals (IRWD), OPKO Health (OPK), Emergent BioSolutions (EBS), and Lexicon Pharmaceuticals (LXRX). These companies are all part of the "pharmaceutical preparations" industry.
Vanda Pharmaceuticals (NASDAQ:VNDA) and Gossamer Bio (NASDAQ:GOSS) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their community ranking, earnings, analyst recommendations, institutional ownership, profitability, valuation, media sentiment, dividends and risk.
Vanda Pharmaceuticals has higher revenue and earnings than Gossamer Bio. Vanda Pharmaceuticals is trading at a lower price-to-earnings ratio than Gossamer Bio, indicating that it is currently the more affordable of the two stocks.
Vanda Pharmaceuticals currently has a consensus target price of $11.00, suggesting a potential upside of 79.15%. Gossamer Bio has a consensus target price of $7.88, suggesting a potential upside of 606.28%. Given Gossamer Bio's higher probable upside, analysts clearly believe Gossamer Bio is more favorable than Vanda Pharmaceuticals.
Vanda Pharmaceuticals received 388 more outperform votes than Gossamer Bio when rated by MarketBeat users. Likewise, 68.15% of users gave Vanda Pharmaceuticals an outperform vote while only 65.63% of users gave Gossamer Bio an outperform vote.
Vanda Pharmaceuticals has a beta of 0.75, suggesting that its share price is 25% less volatile than the S&P 500. Comparatively, Gossamer Bio has a beta of 1.93, suggesting that its share price is 93% more volatile than the S&P 500.
In the previous week, Vanda Pharmaceuticals had 3 more articles in the media than Gossamer Bio. MarketBeat recorded 8 mentions for Vanda Pharmaceuticals and 5 mentions for Gossamer Bio. Vanda Pharmaceuticals' average media sentiment score of 0.99 beat Gossamer Bio's score of 0.76 indicating that Vanda Pharmaceuticals is being referred to more favorably in the media.
Gossamer Bio has a net margin of 0.00% compared to Vanda Pharmaceuticals' net margin of -2.75%. Vanda Pharmaceuticals' return on equity of -0.90% beat Gossamer Bio's return on equity.
88.1% of Vanda Pharmaceuticals shares are owned by institutional investors. Comparatively, 81.2% of Gossamer Bio shares are owned by institutional investors. 7.7% of Vanda Pharmaceuticals shares are owned by insiders. Comparatively, 5.0% of Gossamer Bio shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
Summary
Vanda Pharmaceuticals beats Gossamer Bio on 12 of the 17 factors compared between the two stocks.
Get Vanda Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for VNDA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding VNDA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Vanda Pharmaceuticals Competitors List
Related Companies and Tools
